XOMA Royalty Corporation (NASDAQ:XOMA) Receives Consensus Recommendation of “Hold” from Analysts

XOMA Royalty Corporation (NASDAQ:XOMA) has received a consensus rating of “Hold” from the seven ratings firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $53.75.

XOMA has been the subject of a number of recent research reports. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. Lucid Cap Mkts downgraded XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Benchmark downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. TD Cowen raised XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. Finally, HC Wainwright downgraded XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a research note on Thursday, April 30th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in XOMA. Woodline Partners LP raised its stake in shares of XOMA Royalty by 7.9% in the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after acquiring an additional 12,284 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of XOMA Royalty by 9.1% in the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after acquiring an additional 16,929 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares in the last quarter. Rhumbline Advisers raised its stake in shares of XOMA Royalty by 18.0% in the 2nd quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock valued at $334,000 after acquiring an additional 2,019 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in shares of XOMA Royalty by 12.2% in the 2nd quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company’s stock valued at $411,000 after acquiring an additional 1,775 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Royalty Stock Down 0.5%

XOMA opened at $41.76 on Thursday. XOMA Royalty has a fifty-two week low of $22.29 and a fifty-two week high of $42.81. The business has a 50-day moving average of $39.83 and a 200-day moving average of $31.67. The company has a debt-to-equity ratio of 0.96, a current ratio of 3.59 and a quick ratio of 3.59. The company has a market capitalization of $523.67 million, a PE ratio of 26.60 and a beta of 0.88.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The firm had revenue of $12.32 million for the quarter, compared to analysts’ expectations of $13.91 million. Equities research analysts forecast that XOMA Royalty will post 0.9 EPS for the current fiscal year.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.